图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
免疫病理疾病及治疗学论文学
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN 打印: 2151-8017
ISSN 在线: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

免疫病理疾病及治疗学论文学

DOI: 10.1615/ForumImmunDisTher.v1.i1-2.40
pages 51-64

YY1 as a Therapeutic Target in Cancer

Khimara Naidoo
Academic Foundation Programme, St Thomas’ Hospital, Guys and St Thomas’ National Health Service Foundation Trust, London, United Kingdom
Richard J. Byers
School of Cancer Imaging Sciences, Faculty of Medical and Human Sciences, The University of Manchester; and Department of Histopathology, Manchester Royal Infirmary, Manchester, United Kingdom

ABSTRACT

The transcription factor YY1 controls many divergent cellular processes, including cell proliferation and apoptosis. Because these processes are key to cancer development, the expression of YY1 is altered in many cancers, including lymphoma, prostatic cancer, osteosarcoma, ovarian cancer and leukemia. Its expression has been associated with development of the malignant phenotype, with tumor progression including metastasis, and with survival. Consequently, there has been recent interest in the possible role of YY1 as a therapeutic target. This article reviews the role of YY1 in the control of cell cycle and apoptosis, and provides a detailed discussion of its role in a range of human tumors. YY1 acts to inhibit Fas-mediated apoptosis, although this inhibition is reduced by treatment with rituximab. Similarly, YY1 acts to downregulate TRAIL-induced apoptosis, although this effect can be reversed by treatment with nitric oxide donors, suggesting a possible role for the use of nitric oxide and TRAIL agonists in chemoresistant tumors such as melanoma. Although research is in the early stages, the central position of YY1 in the control of key cellular processes and its association with several cancers renders particularly exciting therapeutic interventions.


Articles with similar content:

Yin Yang 1 in Human Cancer
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 3-4
Richard Byers, Khimara Naidoo, Sarah Nicholson, Helen Whitehouse
Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Anne Arah Cho, Benjamin Bonavida
The Ron Receptor Tyrosine Kinase: A Key Regulator of Inflammation and Cancer Progression
Critical Reviews™ in Immunology, Vol.33, 2013, issue 6
Pamela A. Hankey, Xin Wang
Therapeutic YY1 Inhibitors in Cancer: ALL in ONE
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Benjamin Bonavida
Roles Each of Snail, Yin Yang 1, and RKIP in the Regulation of Tumor Cells Chemo- Immuno-Resistance to Apoptosis
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 1
Sara Huerta-Yepez, Mario I. Vega, Ali R. Jazirehi, Stavroula Baritaki, Benjamin Bonavida